Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.

摘要: Despite considerable advances in the management of urothelial carcinoma (UC), better risk stratification and enhanced detection minimal residual disease are still urgent priorities to prolong survival while avoiding morbidity overtreatment. Circulating tumor cells DNA (CTCs, ctDNA) two biologically distinct "liquid biopsies" that may potentially address this need, although they have been understudied UC date their relative utility is unknown. To end, matched CTC ctDNA samples were collected for a head-to-head comparison pilot study 16 patients with metastatic UC. CTCs defined as cytokeratin- and/or EpCAM-positive using RareCyte direct imaging platform. was assayed PlasmaSelect64 probe-capture assay. 75% had detectable CTCs, 73% somatic mutations, no correlation between count ctDNA. 91% tissue confirmation at least one plasma mutation and, importantly, several clinically actionable mutations detected not found matching tumor. A fraction >2% significantly associated worse overall (p=0.039) whereas (p=0.46). Notably, predefined gene panel high but complete rate UC, similar what has described custom tissue-personalized assay approach. In sum, both liquid biopsies show promise deserve further investigation. PATIENT SUMMARY: New biopsy" blood tests emerging cancer aimed early Our results suggest such provide complementary information: circulating be best studying biological features person's cancer, detection.